Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission

Rhea-AI Summary

Axsome Therapeutics (NASDAQ: AXSM) received formal FDA pre-NDA meeting minutes supporting an NDA submission for AXS-12 (reboxetine) to treat cataplexy in narcolepsy. The FDA agreed the company’s regulatory data package would be sufficient for an NDA filing. Axsome anticipates completing the NDA submission in January 2026, with acceptance subject to the FDA’s review of the complete filing.

AXS-12 clinical work includes three controlled efficacy trials and a completed long-term safety trial. AXS-12 holds Orphan Drug Designation, which may provide seven years of U.S. market exclusivity and potential user-fee waiver if approved.

Positive

• FDA pre-NDA minutes indicate data package is sufficient for NDA submission
• Planned NDA submission timing: January 2026
• AXS-12 has three controlled efficacy trials and a completed long-term safety trial
• AXS-12 holds Orphan Drug Designation with potential 7-year U.S. exclusivity

Negative

• Final NDA acceptance is subject to FDA review and not guaranteed
• Submission not complete until January 2026; timing could change

News Market Reaction – AXSM

+22.75% 5.1x vol

92 alerts

+22.75% News Effect

+15.4% Peak in 6 hr 37 min

+$1.72B Valuation Impact

$9.30B Market Cap

5.1x Rel. Volume

On the day this news was published, AXSM gained 22.75%, reflecting a significant positive market reaction. Argus tracked a peak move of +15.4% during that session. Our momentum scanner triggered 92 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $1.72B to the company's valuation, bringing the market cap to $9.30B at that time. Trading volume was exceptionally heavy at 5.1x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Target NDA timing: January 2026 Efficacy trials: 3 controlled trials Safety trial: 1 long-term trial +3 more

6 metrics

Target NDA timing January 2026 Planned completion of AXS-12 NDA submission for cataplexy in narcolepsy

Efficacy trials 3 controlled trials AXS-12 clinical development program in narcolepsy

Safety trial 1 long-term trial Completed long-term safety trial for AXS-12

Orphan disease threshold Fewer than 200,000 people U.S. definition of rare disease for Orphan Drug Designation

Marketing exclusivity 7 years Potential U.S. exclusivity for AXS-12 upon FDA approval

FDA user fees Application fee waiver Orphan Drug Designation benefit under Prescription Drug User Fee Act

Market Reality Check

Price: $161.46 Vol: Volume 509,245 is in line...

normal vol

$161.46 Last Close

Volume Volume 509,245 is in line with the 20-day average of 488,270 (rel. volume 1.04). normal

Technical Shares at $148.79 are trading above the 200-day MA of $119.41, and about 6.16% below the 52-week high.

Peers on Argus

AXSM was down 1.25% pre-news while key biotech peers like LEGN, CYTK, ABVX, NUVL...

AXSM was down 1.25% pre-news while key biotech peers like LEGN, CYTK, ABVX, NUVL, and RYTM also traded lower (to about -4.65%), indicating broader sector softness, though momentum scanners did not flag a coordinated sector move.

Historical Context

5 past events · Latest: Nov 20 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 20	Investor conferences	Neutral	-2.4%	Planned December 2025 conference appearances and webcast availability.
Nov 06	Pipeline acquisition	Positive	+2.7%	Acquisition of AZD7325 rights for epilepsy, expanding CNS pipeline.
Nov 03	Earnings update	Positive	+0.6%	Strong Q3 2025 revenue growth and pipeline updates including sNDA filing.
Oct 22	Investor conferences	Neutral	-1.3%	Announcements of multiple November 2025 healthcare conference appearances.
Oct 09	Awareness campaign	Positive	+3.2%	Participation in Mental Illness Awareness Week with advocacy programs.

Pattern Detected

Recent news, including acquisitions and earnings, generally saw price moves that aligned with the tone of the announcements, with clinical data headlines sometimes drawing sharper reactions.

Recent Company History

Over the last few months, Axsome reported strong Q3 2025 revenue growth and a narrowed net loss, completed an epilepsy asset acquisition from AstraZeneca, and regularly attended investor conferences. A mental health awareness release also coincided with a positive move. Against this backdrop of expanding CNS pipeline assets and growing commercial sales, the current pre‑NDA update for AXS‑12 in narcolepsy adds a regulatory milestone on top of prior operational momentum.

Market Pulse Summary

The stock surged +22.8% in the session following this news. A strong positive reaction aligns with A...

Analysis

The stock surged +22.8% in the session following this news. A strong positive reaction aligns with Axsome’s steady advancement of CNS assets, as the FDA’s pre‑NDA minutes support an AXS‑12 filing for cataplexy in narcolepsy by January 2026. Prior clinical‑trial headlines produced sizeable moves, and investors have seen both positive and mixed outcomes across programs. Key risks for sustainability would include regulatory review outcomes and how Orphan Drug Designation benefits, such as 7 years of exclusivity, translate into long‑term execution.

Key Terms

new drug application (NDA), u.s. food and drug administration (fda), orphan drug designation, norepinephrine reuptake inhibitor, +3 more

7 terms

new drug application (NDA) regulatory

"New Drug Application (NDA) submission on track for January 2026"

A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.

u.s. food and drug administration (fda) regulatory

"meeting minutes from the U.S. Food and Drug Administration (FDA) supporting an NDA"

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

orphan drug designation regulatory

"AXS-12 has been granted Orphan Drug Designation for the treatment of narcolepsy."

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

norepinephrine reuptake inhibitor medical

"AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor"

A norepinephrine reuptake inhibitor is a medication that blocks the cell ‘pump’ that normally clears the brain chemical norepinephrine, so more of that chemical stays available to nerve cells. Like stopping a drain so water remains in a sink, this can boost alertness, mood and pain control but can also cause side effects tied to an overactive nervous system; investors watch these drugs for their clinical benefits, safety profile and potential market size.

cortical dopamine modulator medical

"norepinephrine reuptake inhibitor and cortical dopamine modulator."

A cortical dopamine modulator is a drug designed to adjust levels or signaling of the brain chemical dopamine specifically in the brain’s cortex, the area involved in thinking, attention and decision-making. For investors, these drugs matter because they target symptoms of psychiatric or neurological disorders and can change a product’s safety, effectiveness and market potential—think of it as tweaking a car’s steering to improve control without overhauling the whole engine.

cataplexy medical

"for the treatment of cataplexy in narcolepsy."

Cataplexy is sudden, brief loss of muscle control triggered by strong emotions such as laughter, surprise or anger; it can range from drooping facial muscles to full body collapse while the person remains conscious. For investors, cataplexy matters because its severity and chronic nature drive demand for treatments, influence clinical trial design and regulatory review, and affect market size, pricing and healthcare costs in neurology and sleep disorder portfolios.

prescription drug user fee act regulatory

"as required by the Prescription Drug User Fee Act."

A federal program that lets drug makers pay fees to the U.S. regulator to fund and speed up the review of new medicines and label changes. Investors care because it affects how quickly a drug can move from testing to market and how predictable approval timelines and regulatory interactions are — like buying a faster lane at a busy checkpoint that can reduce uncertainty about a product’s commercial timing.

AI-generated analysis. Not financial advice.

New Drug Application (NDA) submission on track for January 2026

NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) supporting an NDA submission for AXS-12 in narcolepsy. AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator. The purpose of the meeting was to reach agreement with the FDA on the proposed content and format of the Company’s planned NDA submission including the clinical and nonclinical requirements.

Based on the feedback from the FDA, the Company’s regulatory data package would be sufficient for the submission of an NDA for AXS-12 for the treatment of cataplexy in narcolepsy. Axsome anticipates completing the NDA submission in January 2026. Acceptance of the final NDA will be subject to the FDA’s review of the complete filing.

“We are pleased with the FDA pre-NDA meeting minutes which allow completion of the NDA submission for AXS-12 for the treatment of cataplexy in patients with narcolepsy shortly in January 2026,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “We are excited by the potential of AXS-12 to provide a new, differentiated treatment option to patients living with this debilitating condition, if approved.”

AXS-12’s clinical development program in narcolepsy includes three controlled efficacy trials, and a completed long-term safety trial.

AXS-12 has been granted Orphan Drug Designation for the treatment of narcolepsy. Orphan Drug Designation is granted to promising drugs intended for the safe and effective treatment of rare diseases, defined as those affecting fewer than 200,000 people in the U.S. This designation may entitle Axsome to a period of seven years of marketing exclusivity in the U.S. upon FDA approval and a waiver of the Company’s obligation to pay the FDA application user fees for the product as required by the Prescription Drug User Fee Act.

About Narcolepsy

Narcolepsy is a serious and debilitating orphan neurological condition that causes dysregulation of the sleep-wake cycle and is characterized clinically by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, sleep paralysis, and disrupted nocturnal sleep.^1-3 Cataplexy is seen in an estimated 70% of narcolepsy patients and is a sudden reduction or loss of muscle tone while a patient is awake, typically triggered by strong emotions such as laughter, fear, anger, stress, or excitement.^4-5 Narcolepsy is a life-long condition that interferes with cognitive, psychological, and social functioning, increases the risk of work- and driving-related accidents, and is associated with a 1.5-fold higher mortality rate.^6-8

About AXS-12

AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator under development for the treatment of narcolepsy. AXS-12 is thought to modulate noradrenergic activity to promote maintain tone during wakefulness, and noradrenergic and cortical dopamine signaling to promote wakefulness and enhance cognition. AXS-12 has been granted U.S. Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of narcolepsy. AXS-12 is covered by issued patents providing protection to at least 2039. AXS-12 is an investigational drug product not approved by the FDA.

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit the Company’s website at www.axsome.com.

Forward Looking Statements

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s Sunosi®, Auvelity®, and Symbravo® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of Sunosi, Auvelity, and Symbravo and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

Investors:
Ashley Dong
Director, Investor Relations
(929) 687-1614
adong@axsome.com

Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com

References

1. American Academy of Sleep Medicine. The International Classification of Sleep Disorders. Third Edition (ICSD-3). 2014.
2. National Institute of Neurological Disorders and Stroke. Narcolepsy.https://www.ninds.nih.gov/health-information/disorders/narcolepsy. Accessed September 2024.
3. España RA, Scammell TE. Sleep neurobiology from a clinical perspective. Sleep. 2011 Jul 1;34(7):845-58.
4. Narcolepsy Network. About Narcolepsy. https://narcolepsynetwork.org/about-narcolepsy/. Accessed September 2024.
5. Swick TJ. Treatment paradigms for cataplexy in narcolepsy: past, present, and future. Nat Sci Sleep. 2015 Dec 11;7:159-69.
6. Tadrous R, O'Rourke D, Mockler D, Broderick J. Health-related quality of life in narcolepsy: A systematic review and meta-analysis. J Sleep Res. 2021 Dec;30(6):e13383.
7. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment. J Clin Sleep Med. 2019 Feb 15;15(2):301-334.
8. Ohayon MM, Black J, Lai C, Eller M, Guinta D, Bhattacharyya A. Increased mortality in narcolepsy. Sleep. 2014 Mar 1;37(3):439-44.

FAQ

What did Axsome (AXSM) announce about AXS-12 and the FDA on December 31, 2025?

Axsome said it received FDA pre-NDA meeting minutes indicating the regulatory data package would be sufficient to support an NDA submission for AXS-12 for cataplexy.

When will Axsome submit the NDA for AXS-12 (AXSM)?

Axsome anticipates completing the NDA submission in January 2026, subject to the FDA’s acceptance of the filing.

What clinical evidence does Axsome cite for AXS-12 in narcolepsy?

Axsome reported that AXS-12’s program includes three controlled efficacy trials and a completed long-term safety trial.

What does Orphan Drug Designation mean for AXS-12 (AXSM)?

Orphan designation may provide up to seven years of U.S. market exclusivity upon approval and a waiver of FDA application user fees.

Does FDA pre-NDA agreement guarantee approval for AXS-12 (AXSM)?

No; the FDA indicated the package would be sufficient for submission, but final acceptance and approval depend on the agency’s review of the complete NDA.

How might the January 2026 NDA submission affect AXSM shareholders?

A timely NDA submission could be a material regulatory milestone, but outcome and timing remain subject to FDA review and are not assured.